Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT

Trial Profile

Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Tinzaparin sodium (Primary) ; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms CATCH
  • Sponsors LEO Pharma
  • Most Recent Events

    • 04 Apr 2018 Results assessing impact of renal impairment on the efficacy and safety of anticoagulation in patients with cancer associated thrombosis published in the Thrombosis and Haemostasis
    • 24 Mar 2018 Results published in the Journal of Thrombosis and Haemostasis.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top